tiprankstipranks
Elevance Health, Inc. (CH:A58)
NYSE:A58
Switzerland Market
A58
Elevance Health
RESEARCH TOOLSreports

Elevance Health (A58) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

A58 Analyst Ratings

Moderate Buy
18Ratings
Moderate Buy
13 Buy
5 Hold
0 Sell
Based on 18 analysts giving stock ratings to
Elevance
Health
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

A58 Stock 12 Month Forecast

Average Price Target

$336.91
Based on 18 Wall Street analysts offering 12 month price targets for Elevance Health in the last 3 months. The average price target is $336.91 with a high forecast of $403.69 and a low forecast of $268.32. The average price target represents a ― change from the last price of ―.
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
Highest Price Target$403.69Average Price Target$336.91Lowest Price Target$268.32
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on CH:A58
Andrew Mok CFA
Barclays
Barclays
CHF389.1
Buy
―
Reiterated
06/11/26
Analysts Offer Insights on Healthcare Companies: Amneal Pharmaceuticals (NASDAQ: AMRX), Elevance Health (NYSE: ELV) and Tectonic Therapeutic (NASDAQ: TECX)
Bernstein Analyst forecast on CH:A58
Lance Wilkes
Bernstein
Bernstein
CHF343.71
Buy
―
Reiterated
06/09/26
Bernstein Sticks to Its Buy Rating for Elevance Health (ELV)
J.P. Morgan Analyst forecast on CH:A58
Lisa Gill
J.P. Morgan
J.P. Morgan
CHF333.17→CHF385.86
Buy
―
Reiterated
06/08/26
Elevance Health price target raised to $476 from $411 at JPMorganElevance Health price target raised to $476 from $411 at JPMorgan
Mizuho Securities Analyst forecast on CH:A58
Ann Hynes
Mizuho Securities
Mizuho Securities
CHF352.62→CHF376.94
Buy
―
Reiterated
06/08/26
Elevance Health price target raised to $465 from $435 at MizuhoElevance Health price target raised to $465 from $435 at Mizuho
Morgan Stanley Analyst forecast on CH:A58
Erin Wright
Morgan Stanley
Morgan Stanley
CHF285.34→CHF327.49
Hold
―
Assigned
06/04/26
Elevance Health price target raised to $404 from $352 at Morgan StanleyElevance Health price target raised to $404 from $352 at Morgan Stanley
Wells Fargo Analyst forecast on CH:A58
Stephen Baxter
Wells Fargo
Wells Fargo
CHF316.96
Buy
―
Reiterated
06/04/26
Analysts Are Bullish on Top Healthcare Stocks: Elevance Health (ELV), Indivior (INDV)
Bank of America Securities Analyst forecast on CH:A58
Kevin Fischbeck
Bank of America Securities
Bank of America Securities
CHF352.62→CHF372.89
Buy
―
Reiterated
06/04/26
Bank of America Securities Remains a Buy on Elevance Health (ELV)
Truist Financial Analyst forecast on CH:A58
David S Macdonald
Truist Financial
Truist Financial
CHF303.99→CHF364.78
Buy
―
Assigned
06/01/26
Elevance Health price target raised to $450 from $375 at TruistElevance Health price target raised to $450 from $375 at Truist
UBS Analyst forecast on CH:A58
A.J. Rice
UBS
UBS
CHF324.25→CHF372.89
Buy
―
Reiterated
05/22/26
Elevance Health price target raised to $460 from $400 at UBSElevance Health price target raised to $460 from $400 at UBS
Deutsche Bank Analyst forecast on CH:A58
George Hill
Deutsche Bank
Deutsche Bank
CHF294.26→CHF403.69
Buy
―
Upgraded
05/20/26
Elevance Health upgraded to Buy from Hold at Deutsche BankElevance Health upgraded to Buy from Hold at Deutsche Bank
Evercore ISI Analyst forecast on CH:A58
Elizabeth Anderson CFA
Evercore ISI
Evercore ISI
CHF291.83
Buy
―
Upgraded
05/19/26
Elevance Health added to 'Tactical Outperform' list at Evercore ISIElevance Health added to 'Tactical Outperform' list at Evercore ISI
Goldman Sachs Analyst forecast on CH:A58
Scott Fidel
Goldman Sachs
Goldman Sachs
CHF283.72→CHF299.93
Hold
―
Reiterated
04/24/26
Analysts Offer Insights on Healthcare Companies: Thermo Fisher (NYSE: TMO), Elevance Health (NYSE: ELV) and Eli Lilly & Co (NYSE: LLY)
TD Cowen Analyst forecast on CH:A58
Ryan Langston
TD Cowen
TD Cowen
CHF324.25
Buy
―
Reiterated
04/24/26
Elevance Health: Strong Earnings Momentum and Attractive Valuation Support Buy Rating and $400 Target
Leerink Partners Analyst forecast on CH:A58
Whit Mayo
Leerink Partners
Leerink Partners
CHF289.39→CHF295.07
Hold
―
Reiterated
04/23/26
Elevance Health price target raised to $364 from $357 at LeerinkElevance Health price target raised to $364 from $357 at Leerink
Guggenheim Analyst forecast on CH:A58
Jason Cassorla
Guggenheim
Guggenheim
CHF321.01→CHF323.44
Buy
―
Reiterated
04/23/26
Guggenheim Remains a Buy on Elevance Health (ELV)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on CH:A58
Andrew Mok CFA
Barclays
Barclays
CHF389.1
Buy
―
Reiterated
06/11/26
Analysts Offer Insights on Healthcare Companies: Amneal Pharmaceuticals (NASDAQ: AMRX), Elevance Health (NYSE: ELV) and Tectonic Therapeutic (NASDAQ: TECX)
Bernstein Analyst forecast on CH:A58
Lance Wilkes
Bernstein
Bernstein
CHF343.71
Buy
―
Reiterated
06/09/26
Bernstein Sticks to Its Buy Rating for Elevance Health (ELV)
J.P. Morgan Analyst forecast on CH:A58
Lisa Gill
J.P. Morgan
J.P. Morgan
CHF333.17→CHF385.86
Buy
―
Reiterated
06/08/26
Elevance Health price target raised to $476 from $411 at JPMorganElevance Health price target raised to $476 from $411 at JPMorgan
Mizuho Securities Analyst forecast on CH:A58
Ann Hynes
Mizuho Securities
Mizuho Securities
CHF352.62→CHF376.94
Buy
―
Reiterated
06/08/26
Elevance Health price target raised to $465 from $435 at MizuhoElevance Health price target raised to $465 from $435 at Mizuho
Morgan Stanley Analyst forecast on CH:A58
Erin Wright
Morgan Stanley
Morgan Stanley
CHF285.34→CHF327.49
Hold
―
Assigned
06/04/26
Elevance Health price target raised to $404 from $352 at Morgan StanleyElevance Health price target raised to $404 from $352 at Morgan Stanley
Wells Fargo Analyst forecast on CH:A58
Stephen Baxter
Wells Fargo
Wells Fargo
CHF316.96
Buy
―
Reiterated
06/04/26
Analysts Are Bullish on Top Healthcare Stocks: Elevance Health (ELV), Indivior (INDV)
Bank of America Securities Analyst forecast on CH:A58
Kevin Fischbeck
Bank of America Securities
Bank of America Securities
CHF352.62→CHF372.89
Buy
―
Reiterated
06/04/26
Bank of America Securities Remains a Buy on Elevance Health (ELV)
Truist Financial Analyst forecast on CH:A58
David S Macdonald
Truist Financial
Truist Financial
CHF303.99→CHF364.78
Buy
―
Assigned
06/01/26
Elevance Health price target raised to $450 from $375 at TruistElevance Health price target raised to $450 from $375 at Truist
UBS Analyst forecast on CH:A58
A.J. Rice
UBS
UBS
CHF324.25→CHF372.89
Buy
―
Reiterated
05/22/26
Elevance Health price target raised to $460 from $400 at UBSElevance Health price target raised to $460 from $400 at UBS
Deutsche Bank Analyst forecast on CH:A58
George Hill
Deutsche Bank
Deutsche Bank
CHF294.26→CHF403.69
Buy
―
Upgraded
05/20/26
Elevance Health upgraded to Buy from Hold at Deutsche BankElevance Health upgraded to Buy from Hold at Deutsche Bank
Evercore ISI Analyst forecast on CH:A58
Elizabeth Anderson CFA
Evercore ISI
Evercore ISI
CHF291.83
Buy
―
Upgraded
05/19/26
Elevance Health added to 'Tactical Outperform' list at Evercore ISIElevance Health added to 'Tactical Outperform' list at Evercore ISI
Goldman Sachs Analyst forecast on CH:A58
Scott Fidel
Goldman Sachs
Goldman Sachs
CHF283.72→CHF299.93
Hold
―
Reiterated
04/24/26
Analysts Offer Insights on Healthcare Companies: Thermo Fisher (NYSE: TMO), Elevance Health (NYSE: ELV) and Eli Lilly & Co (NYSE: LLY)
TD Cowen Analyst forecast on CH:A58
Ryan Langston
TD Cowen
TD Cowen
CHF324.25
Buy
―
Reiterated
04/24/26
Elevance Health: Strong Earnings Momentum and Attractive Valuation Support Buy Rating and $400 Target
Leerink Partners Analyst forecast on CH:A58
Whit Mayo
Leerink Partners
Leerink Partners
CHF289.39→CHF295.07
Hold
―
Reiterated
04/23/26
Elevance Health price target raised to $364 from $357 at LeerinkElevance Health price target raised to $364 from $357 at Leerink
Guggenheim Analyst forecast on CH:A58
Jason Cassorla
Guggenheim
Guggenheim
CHF321.01→CHF323.44
Buy
―
Reiterated
04/23/26
Guggenheim Remains a Buy on Elevance Health (ELV)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Elevance Health

3 Months
Sarah JamesCantor Fitzgerald
Success Rate
11/17 ratings generated profit
65%
Average Return
+3.85%
Copying Sarah James's trades and holding each position for 3 Months would result in 64.71% of your transactions generating a profit, with an average return of +3.85% per trade.
1 Year
A.J. RiceUBS
Success Rate
24/31 ratings generated profit
77%
Average Return
+18.53%
Copying A.J. Rice's trades and holding each position for 1 Year would result in 77.42% of your transactions generating a profit, with an average return of +18.53% per trade.
2 Years
A.J. RiceUBS
Success Rate
27/31 ratings generated profit
87%
Average Return
+38.59%
Copying A.J. Rice's trades and holding each position for 2 Years would result in 87.10% of your transactions generating a profit, with an average return of +38.59% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

A58 Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
0
0
0
0
0
Buy
22
26
25
31
34
Hold
7
5
9
9
9
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
29
31
34
40
43
In the current month, A58 has received 34 Buy Ratings, 9 Hold Ratings, and 0 Sell Ratings. A58 average Analyst price target in the past 3 months is 336.91.
Each month's total comprises the sum of three months' worth of ratings.

A58 Financial Forecast

A58 Earnings Forecast

Next quarter’s earnings estimate for A58 is $5.01 with a range of $4.90 to $5.44. The previous quarter’s EPS was $10.17. A58 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year A58 has Performed in-line its overall industry.
Next quarter’s earnings estimate for A58 is $5.01 with a range of $4.90 to $5.44. The previous quarter’s EPS was $10.17. A58 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year A58 has Performed in-line its overall industry.

A58 Sales Forecast

Next quarter’s sales forecast for A58 is $39.45B with a range of $38.46B to $40.15B. The previous quarter’s sales results were $40.57B. A58 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year A58 has Performed in-line its overall industry.
Next quarter’s sales forecast for A58 is $39.45B with a range of $38.46B to $40.15B. The previous quarter’s sales results were $40.57B. A58 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year A58 has Performed in-line its overall industry.

A58 Stock Forecast FAQ

What is CH:A58’s average 12-month price target, according to analysts?
Based on analyst ratings, Elevance Health, Inc.’s 12-month average price target is 336.91.
    What is CH:A58’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:A58, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Elevance Health, Inc. a Buy, Sell or Hold?
        Elevance Health, Inc. has a consensus rating of Moderate Buy, which is based on 13 buy ratings, 5 hold ratings and 0 sell ratings.
          What is Elevance Health, Inc.’s share price target?
          The average share price target for Elevance Health, Inc. is 336.91. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is $403.69 ,and the lowest forecast is $268.32. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Elevance Health, Inc.?
            Elevance Health, Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 18 Wall Streets Analysts.
              How can I buy shares of Elevance Health, Inc.?
              To buy shares of CH:A58, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.